CoChat
Cited by 37

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia

Rentsch, Peggy, Stayte, Sandy, Egan, Timothy, Clark, Ian, Vissel, Bryce · 2020 · Neurobiology of Disease

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2019.104646

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 62

  1. Andersson, 1999, Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal Prodynorphin mRNA in a rat model of Parkinson’s disease, Neurobiol. Dis., 6, 461, 10.1006/nbdi.1999.0259 · DOI · Paper page
  2. Ashton, 2007, The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration, Curr. Neuropharmacol., 5, 73, 10.2174/157015907780866884 · DOI · Paper page
  3. Benito, 2003, Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains, J. Neurosci., 23, 11136, 10.1523/JNEUROSCI.23-35-11136.2003 · DOI · Paper page
  4. Benito, 2008, Cannabinoid CB2 receptors in human brain inflammation, Br. J. Pharmacol., 153, 277, 10.1038/sj.bjp.0707505 · DOI · Paper page
  5. Bisogno, 2010, Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders, CNS Neurol. Disord. Drug Targets, 9, 564, 10.2174/187152710793361568 · DOI · Paper page
  6. Blanpied, 2005, Amantadine inhibits NMDA receptors by accelerating channel closure during channel block, J. Neurosci., 25, 3312, 10.1523/JNEUROSCI.4262-04.2005 · DOI · Paper page
  7. Brigham, 2018, Pharmacokinetic/pharmacodynamic correlation analysis of amantadine for levodopa-induced dyskinesia, J. Pharmacol. Exp. Ther., 367, 373, 10.1124/jpet.118.247650 · DOI
  8. Buckley, 2000, Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor, Eur. J. Pharmacol., 396, 141, 10.1016/S0014-2999(00)00211-9 · DOI · Paper page
  9. Cenci, 2007, Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson’s disease in rats and mice, Curr. Protoc. Neurosci. Chapter 9, Unit, 9, 25
  10. Danysz, 1997, Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies, Neurosci. Biobehav. Rev., 21, 455, 10.1016/S0149-7634(96)00037-1 · DOI · Paper page
  11. Di Marzo, 2018, New approaches and challenges to targeting the endocannabinoid system, Nat. Rev. Drug Discov., 17, 623, 10.1038/nrd.2018.115 · DOI · Paper page
  12. Doo, 2014, Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson’s disease mouse model, BMC Complement. Altern. Med., 14, 107, 10.1186/1472-6882-14-107 · DOI
  13. dos-Santos-Pereira, 2016, Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action, Neurobiol. Dis., 94, 179, 10.1016/j.nbd.2016.06.013 · DOI
  14. Fasano, 2010, Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia, Proc. Natl. Acad. Sci. U. S. A., 107, 21824, 10.1073/pnas.1012071107 · DOI
  15. Fernández-Trapero, 2017, Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis, Dis. Model. Mech., 10, 551
  16. Ferrer, 2003, Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias, Eur. J. Neurosci., 18, 1607, 10.1046/j.1460-9568.2003.02896.x · DOI
  17. Fieblinger, 2014, Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia, Nat. Commun., 5, 5316, 10.1038/ncomms6316 · DOI · Paper page
  18. Finseth, 2015, Self-reported efficacy of Cannabis and other complementary medicine modalities by Parkinson’s disease patients in Colorado. Evidence-Based Complement, Altern. Med., 1
  19. Fox, 2002, Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson’s disease, Mov. Disord., 17, 1180, 10.1002/mds.10289 · DOI · Paper page
  20. Girasole, 2018, A subpopulation of striatal neurons mediates levodopa-induced dyskinesia, Neuron, 97, 787, 10.1016/j.neuron.2018.01.017 · DOI
  21. Gómez-Gálvez, 2016, Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson’s disease, Prog. Neuro-Psychopharmacol. Biol. Psychiatr., 64, 200, 10.1016/j.pnpbp.2015.03.017 · DOI · Paper page
  22. Gundersen, 1987, The efficiency of systematic sampling in stereology and its prediction, J. Microsc., 147, 229, 10.1111/j.1365-2818.1987.tb02837.x · DOI · Paper page
  23. Hanus, 1999, HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor, Proc. Natl. Acad. Sci. U. S. A., 96, 14228, 10.1073/pnas.96.25.14228 · DOI · Paper page
  24. Javed, 2016, Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson’s disease, Front. Neurosci., 10, 321, 10.3389/fnins.2016.00321 · DOI · Paper page
  25. Jordan, 2019, Progress in brain cannabinoid CB2 receptor research: from genes to behavior, Neurosci. Biobehav. Rev., 98, 208, 10.1016/j.neubiorev.2018.12.026 · DOI · Paper page
  26. Keren-Shaul, 2017, A unique microglia type associated with restricting development of Alzheimer’s disease, Cell, 169, 1276, 10.1016/j.cell.2017.05.018 · DOI · Paper page
  27. Khakh, 2015, Diversity of astrocyte functions and phenotypes in neural circuits, Nat. Neurosci., 18, 942, 10.1038/nn.4043 · DOI · Paper page
  28. Kim, 2015, Chronic activation of CB2 cannabinoid receptors in the hippocampus increases excitatory synaptic transmission, J. Physiol., 593, 871, 10.1113/jphysiol.2014.286633 · DOI
  29. Kim, 2012, Microglia-inhibiting activity of Parkinson’s disease drug amantadine, Neurobiol. Aging, 33, 2145, 10.1016/j.neurobiolaging.2011.08.011 · DOI
  30. Li, 2016, Deletion of CB2 cannabinoid receptors reduces synaptic transmission and long-term potentiation in the mouse hippocampus, Hippocampus, 26, 275, 10.1002/hipo.22558 · DOI
  31. Lotan, 2014, Cannabis (Medical Marijuana) treatment for motor and non–motor symptoms of Parkinson disease, Clin. Neuropharmacol., 37, 41, 10.1097/WNF.0000000000000016 · DOI · Paper page
  32. Lundblad, 2004, A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function, Neurobiol. Dis., 16, 110, 10.1016/j.nbd.2004.01.007 · DOI · Paper page
  33. MacCallum, 2018, Practical considerations in medical cannabis administration and dosing, Eur. J. Intern. Med., 49, 12, 10.1016/j.ejim.2018.01.004 · DOI · Paper page
  34. Manson, 2012, Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life, J. Park. Dis., 2, 189
  35. Martinez, 2012, The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats, Neurosci. Res., 72, 236, 10.1016/j.neures.2011.12.006 · DOI
  36. Morgese, 2007, Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson’s disease: role of CB1 and TRPV1 receptors, Exp. Neurol., 208, 110, 10.1016/j.expneurol.2007.07.021 · DOI · Paper page
  37. Mulas, 2016, Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson’s disease, Exp. Neurol., 286, 83, 10.1016/j.expneurol.2016.09.013 · DOI
  38. Ossola, 2011, Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected], Neuropharmacology, 61, 574, 10.1016/j.neuropharm.2011.04.030 · DOI
  39. Pandey, 2017, Levodopa-induced dyskinesia: clinical features, pathophysiology, and medical management, Ann. Indian Acad. Neurol., 20, 190, 10.4103/aian.AIAN_239_17 · DOI
  40. Paquette, 2012, Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson’s disease: role of NMDA vs. 5-HT1A receptors, Eur. J. Neurosci., 36, 3224, 10.1111/j.1460-9568.2012.08243.x · DOI
  41. Pavón, 2006, ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in Hemiparkinsonian mice, Biol. Psychiatry, 59, 64, 10.1016/j.biopsych.2005.05.044 · DOI · Paper page
  42. Perez-Lloret, 2018, Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia, J. Neural Transm., 125, 1237, 10.1007/s00702-018-1869-1 · DOI
  43. Price, 2009, WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease, Eur. J. Neurosci., 29, 2177, 10.1111/j.1460-9568.2009.06764.x · DOI · Paper page
  44. Priller, 2019, Targeting microglia in brain disorders, Science (80-), 365, 32, 10.1126/science.aau9100 · DOI
  45. Rentsch, 2019, Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on l-Dopa induced dyskinesia, BMC Neurosci., 20, 5, 10.1186/s12868-019-0487-7 · DOI
  46. Schallert, 2000, CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury, Neuropharmacology, 39, 777, 10.1016/S0028-3908(00)00005-8 · DOI · Paper page
  47. Schuler, 2009, Optimized surgical techniques and postoperative care improve survival rates and permit accurate telemetric recording in exercising mice, BMC Vet. Res., 5, 28, 10.1186/1746-6148-5-28 · DOI
  48. Sebastianutto, 2016, Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists, Neurobiol. Dis., 96, 156, 10.1016/j.nbd.2016.09.001 · DOI
  49. Sharma, 2018, Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease, Ther. Clin. Risk Manag., 14, 665, 10.2147/TCRM.S144481 · DOI
  50. Smith, 2012, Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia, Behav. Brain Res., 226, 281, 10.1016/j.bbr.2011.09.025 · DOI
  51. Song, 2014, The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats, Drug Des. Devel. Ther., 8, 2173
  52. Stayte, 2015, Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson’s disease, PLoS One, 10, 10.1371/journal.pone.0124325 · DOI
  53. Stayte, 2017, Activin A inhibits MPTP and LPS-induced increases in inflammatory cell populations and loss of dopamine neurons in the mouse midbrain in vivo, PLoS One, 12, 10.1371/journal.pone.0167211 · DOI
  54. Suárez, 2014, L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice, Biol. Psychiatry, 75, 711, 10.1016/j.biopsych.2013.05.006 · DOI · Paper page
  55. Tay, 2018, Unique microglia recovery population revealed by single-cell RNAseq following neurodegeneration, Acta Neuropathol. Commun, 6, 87, 10.1186/s40478-018-0584-3 · DOI
  56. Thiele, 2012, Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson’s disease, J. Vis. Exp., 1
  57. Thiele, 2014, Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models, Neurobiol. Dis., 71, 334, 10.1016/j.nbd.2014.08.006 · DOI
  58. Thorlund, 2012, Stability of additive treatment effects in multiple treatment comparison meta-analysis: a simulation study, Clin. Epidemiol., 4, 75
  59. Venderová, 2004, Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms, Mov. Disord., 19, 1102, 10.1002/mds.20111 · DOI · Paper page
  60. Walsh, 2010, The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats, Brain Res., 1363, 40, 10.1016/j.brainres.2010.09.086 · DOI
  61. Winkler, 2002, L-DOPA-induced dyskinesia in the Intrastriatal 6-hydroxydopamine model of Parkinson’s disease: relation to motor and cellular parameters of nigrostriatal function, Neurobiol. Dis., 10, 165, 10.1006/nbdi.2002.0499 · DOI · Paper page
  62. Zhang, 2013, Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses, J. Neurosci., 33, 11655, 10.1523/JNEUROSCI.0288-13.2013 · DOI

Cited by

See all 37

Metadata

Authors
Rentsch, P., Stayte, S., Egan, T., Clark, I., & Vissel, B.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2020-02
Volume
134
Pages
104646
ISSN
0969-9961
Cited by
37
References
15
Language
en
Licence
Funders
Parkinson's NSW

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.